Page 26 - ARNM-2-2

Advances in Radiotherapy
& Nuclear Medicine Melanoma brain metastatic treatment

doses, we must not overlook the possible occurrence of for survival in melanoma patients with brain metastases.
unfavorable adverse events attributed to brain penetration Cancer. 2011;117(8):1687-1696.
by ICIs. Therefore, future prospective studies should doi: 10.1002/cncr.25634
focus more on monitoring the safety profile of combined
treatments, which is instrumental for the subsequent phase 5. Kamp MA, Rapp M, Slotty PJ, et al. Incidence of local in-brain
3 studies to confirm the effectiveness of the strategy, thus progression after supramarginal resection of cerebral
metastases. Acta Neurochir (Wien). 2015;157(6):905-910;
providing more data to enable evidence-based decision- discussion 910-911.
making.
doi: 10.1007/s00701-015-2405-9
Acknowledgments 6. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-

None. brain radiotherapy versus observation after radiosurgery
or surgical resection of one to three cerebral metastases:
Funding Results of the EORTC 22952-26001 study. J Clin Oncol.
2011;29(2):134-141.
None.
doi: 10.1200/JCO.2010.30.1655
Conflict of interest 7. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative

The authors declare that they have no competing interests. stereotactic radiosurgery versus observation for completely
resected brain metastases: A single-centre, randomised,
Author contributions controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040-1048.

Conceptualization: Silvia Comas Anton, Maria Gabriela doi: 10.1016/S1470-2045(17)30414-X
Antelo Redondo 8. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative
Writing – original draft: Silvia Comas Anton, Gerard Meca stereotactic radiosurgery compared with whole brain
Santamaria, Maria Gabriela Antelo Redondo radiotherapy for resected metastatic brain disease (NCCTG
Writing – review & editing: All authors N107C/CEC·3): A multicentre, randomised, controlled,
phase 3 trial. Lancet Oncol. 2017;18(8):1049-1060.
Ethics approval and consent to participate doi: 10.1016/S1470-2045(17)30441-2

Not applicable. 9. Gondi V, Bauman G, Bradfield L, et al. Radiation therapy
for brain metastases: An ASTRO clinical practice guideline.
Consent for publication Pract Radiat Oncol. 2022;12(4):265-282.

Not applicable. doi: 10.1016/j.prro.2022.02.003
Availability of data 10. Schiff D, Messersmith H, Brastianos PK, et al. Radiation
therapy for brain metastases: ASCO guideline endorsement
Not applicable. of ASTRO guideline. J Clin Oncol. 2022;40(20):2271-2276.

References doi: 10.1200/JCO.22.00333
1. Diaz MJ, Mark I, Rodriguez D, et al. Melanoma brain 11. Yamamoto M, Sato Y, Higuchi Y, Kasuya H, Barfod BE.
metastases: A systematic review of opportunities for earlier A cohort study of stereotactic radiosurgery results for
detection, diagnosis, and treatment. Life. 2023;13(3):828. patients with 5 to 15 versus 2 to 4 brain metastatic tumors.
Adv Radiat Oncol. 2019;5(3):358-368.
doi: 10.3390/life13030828
doi: 10.1016/j.adro.2019.11.001
2. Phadke M, Ozgun A, Eroglu Z, Smalley KSM. Melanoma
brain metastases: Biological basis and novel therapeutic 12. Lehrer EJ, Peterson JL, Zaorsky NG, et al. Single versus
strategies. Exp Dermatol. 2022;31(1):31-42. multifraction stereotactic radiosurgery for large brain
metastases: An international meta-analysis of 24 trials. Int J
doi: 10.1111/exd.14286 Radiat Oncol Biol Phys. 2019;103(3):618-630.
3. Rhun EL, Guckenberger M, Smits M, et al. EANOeESMO doi: 10.1016/j.ijrobp.2018.10.038
clinical practice guidelines for diagnosis, treatment and
follow-up of patients with brain metastasis from solid 13. Brown PD, Pugh S, Laack NN, et al. Memantine for
tumors. Ann Oncol. 2021;32(11):1332-1347. the prevention of cognitive dysfunction in patients
receiving whole-brain radiotherapy: A randomized,
doi: 10.1016/j.annonc.2021.07.016 double-blind, placebo-controlled trial. Neuro Oncol.
4. Davies MA, Liu P, McIntyre S, et al. Prognostic factors 2013;15(10):1429-1437.

Volume 2 Issue 2 (2024) 6 doi: 10.36922/arnm.3499